The diagnostic value of screening tests in the second trimester of pregnancy regarding the incidence of preeclampsia in late pregnancy in women referred to the perinatology clinic of Sabzevar University of Medical Sciences in 2021-2022

Document Type : Original Article

Authors

1 General practitioner, Student Research Committee, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

2 Associate Professor, Department of Anesthesiology, Facultyof Medicine, Sabzevar University of Medical Sciences, Sabzevar ,Iran.

3 Assistant Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

4 Assistant Professor, Department of Community Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

5 M.Sc. in Midwifery Education, Vice President of Treatment, Sabzevar University of Medical Sciences, Sabzevar, Iran.

6 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

10.22038/ijogi.2024.75271.5874

Abstract

Introduction: Preeclampsia occurs as a result of poor perfusion of the placental vessels, which in turn, arises from insufficient regeneration of the spiral arteries of the maternal uterus. Early diagnosis and prediction of preeclampsia (PE) may prevent fetal and maternal complications. The present study was conducted with aim to determine the diagnostic value of screening tests in the second trimester of pregnancy regarding the incidence of preeclampsia in late pregnancy.
Methods: This cross-sectional study was conducted during 2021-2022 in the Perinatology Clinic of Sabzevar. In this study, 150 patients with high risk of preeclampsia in the screening of the second trimester of pregnancy were included. Preeclampsia was diagnosed using hospitalization documents. Data were analyzed using descriptive tests, ROC curve, and the Area under the Curve (AUC). P<0.05 was considered statistically significant.
Results: Of 150 high-risk individuals in terms of preeclampsia, only 12 (8%) were diagnosed with preeclampsia. The accuracy of different factors to predict preeclampsia was obtained: 0.45 for AFP, 0.43 for inhibin a, 0.27 for beta HCG, and 0.57 for UE3. With 95% confidence, UE3 level between 0.42 and 0.73 had the best diagnostic value for preeclampsia. The highest sensitivity and specificity of UE3 for predicting preeclampsia was 66% and 49%, respectively for 0.74 MOM.
Conclusion: The reduction of unconjugated estriol can be used as a biomarker in predicting preeclampsia. The high risk of screening in the second trimester of pregnancy cannot merely predict the risk of preeclampsia.

Keywords

Main Subjects

References

  1. Neuman RI, Alblas van der Meer MM, Nieboer D, Saleh L, Verdonk K, Kalra B, et al. PAPP‐A2 and inhibin a as novel predictors for pregnancy complications in women with suspected or confirmed preeclampsia. Journal of the American Heart Association 2020; 9(19):e018219.
  2. Hitzerd E, Neuman RI, Broekhuizen M, Simons SH, Schoenmakers S, Reiss IK, et al. Transfer and vascular effect of endothelin receptor antagonists in the human placenta. Hypertension 2020; 75(3):877-84.
  3. Long W, Zhou Q, Wang H, Lu B, Chen Y, Zhang B, et al. Second-trimester maternal serum screening biomarkers in the risk assessment for preeclampsia. Annals of Clinical & Laboratory Science 2018; 48(3):308-13.
  4. Sharabi-Nov A, Premru Sršen T, Kumer K, Fabjan Vodušek V, Fabjan T, Tul N, et al. Maternal Serum Inhibin-A Augments the Value of Maternal Serum PlGF and of sFlt-1/PlGF Ratio in the Prediction of Preeclampsia and/or FGR Near Delivery—A Secondary Analysis. Reproductive Medicine 2021; 2(1):35-49.
  5. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circulation research 2019; 124(7):1094-112.
  6. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nature Reviews Nephrology 2014; 10(8):466-80.
  7. Yue CY, Zhang CY, Ni YH, Ying CM. Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome?. Plos one 2020; 15(5):e0232634.
  8. Yue CY, Zhang CY, Ying CM. Serum markers in quadruple screening associated with adverse pregnancy outcomes: A case–control study in China. Clinica chimica acta 2020; 511:278-81.
  9. Shah S, Aamir M, Haroon ZH, Bibi A, Akber R, Khalid UB. Determination of Serum Inhibin-A Levels in Differentiating Pre-Eclampsia and Gestational Hypertension. Pakistan Armed Forces Medical Journal 2022; 72(3):1027-31.
  10. Panwar M, Kumari A, Arora R, Singh V, Bansiwal R. Raised neutrophil lymphocyte ratio and serum beta hCG level in early second trimester of pregnancy as predictors for development and severity of preeclampsia. Drug discoveries & therapeutics 2019; 13(1):34-7.
  11. Farzaneh F, Sharifi M, Nourinasab N, Younesi S. Value of α-fetoprotein, β-HCG, inhibin A, and UE3 at second trimester for early screening of preeclampsia. Asian Pacific Journal of Reproduction 2019; 8(1):30-3.
  12. Izairi P, Velickova N, Stojovski M, Izairi A. The Importance of Prenatal Screening of Serum Biomarkers of Quadriple Test and Fetoplacental Unit in the Prediction of Perinatal Risk and Pregnancy Outcome. Acta Medica Balkanica: International Journal of Medical Sciences 2022; 7(13-14):129-42.
  13. Kim YR, Jung I, Heo SJ, Chang SW, Cho HY. A preeclampsia risk prediction model based on maternal characteristics and serum markers in twin pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine 2021; 34(21):3623-8.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 27, Issue 6
August 2024
Pages 10-17

Files

Share

How to cite

Statistics